N/A N=81 Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus
Humerus Fracture Metastatic Bone Disease
Primary: Change in Pain — -52.7 units on a scale — p=0.615
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Orthopaedic Treatment Proximal Humeral Fractures
Proximal Humeral Fracture
Primary: Constant Scale Evaluation at 3 Months and 12 Months From the Date of Trauma — 40.1; 51.8 units on a scale — p=<0.01
N/A N=40 Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures
A02.835.232.087.090.400.400
Primary: Effectiveness Will be Measured for AMERICAN SHOULDER AND ELBOW (ASES) Score — 66; 77 score on a scale — p=0.048
N/A N=63 Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures
Proximal Humeral Fractures
Primary: Shoulder Flexion — 150; 146 Degrees
N/A N=118 The Outcomes of Proximal Humerus Fractures in Children
Humeral Fractures
Primary: Number of Participants With Indicated Status as Assessed by Mail Questionnaire Upper Extremities Functional Index (UEFI) — 4; 4; 24 Participants
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
N/A N=23 Humeral Shaft Pseudoarthrosis Treated With Bone Autograft Versus Platelet Rich Plasma
Pseudoarthrosis
Primary: Stans Scale — 2.7; 3.0 units on a scale
N/A N=60 Fixation of Unstable Distal Radius Fractures
Distal Radius Fractures
Primary: Average Difference Between Michigan Hand Outcomes Questionnaire Scores — 85.2; 91.8 units on a scale
Phase 3 N=261 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Breast Cancer · Lung Cancer · Metastatic Cancer
Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844
N/A N=130 Functional Status, Morbidity and Mortality in Cemented Versus Press-Fit Hemiarthroplasty
Femoral Neck Fracture
Primary: Mortality — 23.1; 20.1 pecent
N/A N=156 A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Distal Femur Fractures
Femoral Fractures
Primary: EQ-5D — 69.23; 72.81; 74.24; 73.04 units on a scale
Phase 2 N=36 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
N/A N=52 Anatomical Shoulder™ Fracture PMCF Study
Fracture
Primary: Functional Performance — 57.7 score on a scale
N/A N=850 Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
Metastatic Cancer · Pain
Primary: Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment — 28.0; 32.0 percentage of participants — p=0.03
Phase 2 N=35 Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants
N/A N=115 ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=139 Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
Breast Cancer · Prostate Cancer · Bone Neoplasms
Primary: Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 — -71.1; -68.4 Percentage change in betaCTX
Phase 2 N=12 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
N/A N=102 Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
N/A N=20 Reduction and Fixation of Metatarsal Neck Fracture by Metaizeau's Technique
Displaced Metatarsal Neck Fracture
Primary: Time of Union — 5.8 weeks
N/A N=12 Effect of High Doses of Radiation on Bone Structure and Metabolism
Malignant Bone Tumors
Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3
Phase 3 N=6,097 S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
Breast Cancer
Primary: Disease-free Survival — 88; 88; 87 percentage of analyzed participants — p=0.49
N/A N=33 Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures
Tibial Fractures
Primary: Duration of Time the Patient Was in the OR as a Measure of Effectiveness of the Treatment — 107.0 Minutes
Phase 3 N=122 Effect of Teriparatide on Hip Fracture Healing
Femur Neck Fracture
Primary: Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture — 87; 86 percentage of participants
Phase 3 N=3,323 Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Disease Free Survival. — 81.0; 79.6 percentage of patients
Phase 2 N=45 Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
Phase 3 N=160 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Bone Metastases
Primary: Number of Intent- to- Treat Patients With Pain Response by Treatment — 19; 34; 24; 36 Participants — p=.03
N/A N=5 Proximal Humerus Site for Anesthesia
Intraosseous Vascular Access
Primary: Intraosseous Infusion Flow Rate — 2433.33 mL / hour
N/A N=28 Rapid Radiation Therapy for Painful Osseous Metastatic Disease
Bone Metastases
Primary: Number of Participants With a Complete Response, Partial Response, or Stable Pain After Receiving Treatment Via the STAT RT Workflow at 12-months — 9 Participants